semaglutide off fda shortage list Despite ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market Semaglutide's removal from the FDA

Who Is the GLP-1 Consumer

Here's what they found at 64 weeks: Average weight loss of 16.6% with full adherence (vs 2.7% with placebo) 13.6% average loss even for people who didnt stick to the full dose 79.2% of participants on the pill lost at least 5% of body weight 63% lost at least 10% 30% lost 20% or more Serious adverse events were less frequent in the semaglutide group (3.9%) than placebo (8.8%) Just to put the numbers into context, 16% for a 100 kg man is 16 kg

For example, liraglutide, another widely used GLP-1 receptor agonist, has been studied extensively, and the evidence does not suggest a significant risk of blood clots

Exenatide, dulaglutide, and albiglutide did not meet the test criteria, so the three drugs mentioned above were not shown to be associated with AKI